{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:08:16Z","timestamp":1766167696217,"version":"3.48.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03447-z","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T07:52:53Z","timestamp":1739951573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the efficacy and safety of neuroprotective agents in optic neuritis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"45","author":[{"given":"Abdulrahman Hameed","family":"Alsubhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Khalid","family":"Althagafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Latifah","family":"Alhamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahaf Ali","family":"Alothman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman Ali Ahmed","family":"Alothman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah Saeed","family":"Alghorair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahad Abdullah","family":"Alruwaili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nooran","family":"Badeeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"3447_CR1","first-page":"599","volume-title":"Walsh and Hoyt's Neuro-ophthalmology","author":"RW Beck","year":"1998","unstructured":"Beck RW (1998) Optic Neuritis. In: Miller NR, Newman NJ (eds) Walsh and Hoyt\u2019s Neuro-ophthalmology, 5th edn. Williams and Wilkins, Baltimore, pp 599\u2013647","edition":"5"},{"key":"3447_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.6.727","author":"Optic Neuritis Study Group","year":"2008","unstructured":"Optic Neuritis Study Group (2008) Multiple sclerosis risk after optic neuritis. Arch Neurol. https:\/\/doi.org\/10.1001\/archneur.65.6.727","journal-title":"Arch Neurol"},{"issue":"9","key":"3447_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri3871","volume":"15","author":"CA Dendrou","year":"2015","unstructured":"Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15(9):545\u2013558. https:\/\/doi.org\/10.1038\/nri3871","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3447_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01658107.2021.1964541","volume":"46","author":"SJ Hickman","year":"2022","unstructured":"Hickman SJ, Petzold A (2022) Update on optic neuritis: an international view. Neuro-Ophthalmology 46(1):1\u201318. https:\/\/doi.org\/10.1080\/01658107.2021.1964541","journal-title":"Neuro-Ophthalmology"},{"issue":"5","key":"3447_CR5","first-page":"1017","volume":"41","author":"SR Cole","year":"2000","unstructured":"Cole SR, Beck RW, Moke PS, Gal RL, Long DT (2000) The national eye institute visual function questionnaire: experience of the ONTT. Optic neuritis treatment trial. Invest Ophthalmol Vis Sci 41(5):1017\u20131021","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"3447_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0002-9394(14)70814-1","volume":"124","author":"P Cleary","year":"1997","unstructured":"Cleary P, Bourque L, Backlund J, Miksala P (1997) For the optic neuritis study group, Beck R. visual symptoms after optic neuritis. Results from the optic neuritis treatment trial. Am J Ophthalmol 124(2):275. https:\/\/doi.org\/10.1016\/S0002-9394(14)70814-1","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"3447_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199202273260901","volume":"326","author":"RW Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326(9):581\u2013588. https:\/\/doi.org\/10.1056\/NEJM199202273260901","journal-title":"N Engl J Med"},{"issue":"2","key":"3447_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.mayocp.2013.11.002","volume":"89","author":"DM Wingerchuk","year":"2014","unstructured":"Wingerchuk DM, Carter JL (2014) Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 89(2):225\u2013240. https:\/\/doi.org\/10.1016\/j.mayocp.2013.11.002","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"3447_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/WCO.0000000000000418","volume":"30","author":"A Petzold","year":"2017","unstructured":"Petzold A (2017) Neuroprotection and visual function after optic neuritis. Curr Opin Neurol 30(1):67\u201373. https:\/\/doi.org\/10.1097\/WCO.0000000000000418","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"3447_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/brain\/awu335","volume":"138","author":"LJ Balcer","year":"2015","unstructured":"Balcer LJ, Miller DH, Reingold SC, Cohen JA (2015) Vision and vision-related outcome measures in multiple sclerosis. Brain 138(1):11\u201327. https:\/\/doi.org\/10.1093\/brain\/awu335","journal-title":"Brain"},{"issue":"9","key":"3447_CR11","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1093\/brain\/awq146","volume":"133","author":"APD Henderson","year":"2010","unstructured":"Henderson APD, Altmann DR, Trip AS et al (2010) A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain 133(9):2592\u20132602. https:\/\/doi.org\/10.1093\/brain\/awq146","journal-title":"Brain"},{"issue":"2","key":"3447_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ophtha.2005.10.017","volume":"113","author":"C Fraser","year":"2006","unstructured":"Fraser C, Klistorner A, Graham S, Garrick R, Billson F, Grigg J (2006) Multifocal visual evoked potential analysis of inflammatory or demyelinating optic neuritis. Ophthalmology 113(2):315-323.e2. https:\/\/doi.org\/10.1016\/j.ophtha.2005.10.017","journal-title":"Ophthalmology"},{"key":"3447_CR13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2020) The PRISMA statement: an updated guideline for reporting systematic reviews. BMJ 2021:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"3447_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"2","key":"3447_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ana.23573","volume":"72","author":"KW S\u00fchs","year":"2012","unstructured":"S\u00fchs KW, Hein K, S\u00e4ttler MB et al (2012) A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol 72(2):199\u2013210. https:\/\/doi.org\/10.1002\/ana.23573","journal-title":"Ann Neurol"},{"issue":"12","key":"3447_CR16","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1474-4422(21)00322-7","volume":"20","author":"WA Lagr\u00e8ze","year":"2021","unstructured":"Lagr\u00e8ze WA, K\u00fcchlin S, Ihorst G et al (2021) Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study. Lancet Neurol 20(12):991\u20131000. https:\/\/doi.org\/10.1016\/S1474-4422(21)00322-7","journal-title":"Lancet Neurol"},{"issue":"3","key":"3447_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(16)00004-1","volume":"15","author":"R Raftopoulos","year":"2016","unstructured":"Raftopoulos R, Hickman SJ, Toosy A et al (2016) Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 15(3):259\u2013269. https:\/\/doi.org\/10.1016\/S1474-4422(16)00004-1","journal-title":"Lancet Neurol"},{"key":"3447_CR18","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1007\/s10072-020-04360-2\/Published","volume":"41","author":"S Yadegari","year":"2020","unstructured":"Yadegari S, Gholizade A, Ghahvehchian H, Masoud Fard A (2020) Effect of phenytoin on retinal ganglion cells in acute isolated optic neuritis. Neurol Sci 41:2477\u20132483. https:\/\/doi.org\/10.1007\/s10072-020-04360-2\/Published","journal-title":"Neurol Sci"},{"issue":"6","key":"3447_CR19","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00417-011-1894-3","volume":"250","author":"MR Esfahani","year":"2012","unstructured":"Esfahani MR, Harandi ZA, Movasat M et al (2012) Memantine for axonal loss of optic neuritis. Graefe\u2019s Arch Clinic Exp Ophthalmol 250(6):863\u2013869. https:\/\/doi.org\/10.1007\/s00417-011-1894-3","journal-title":"Graefe\u2019s Arch Clinic Exp Ophthalmol"},{"issue":"12","key":"3447_CR20","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1007\/s00417-022-05720-8","volume":"260","author":"D Motamedi","year":"2022","unstructured":"Motamedi D, Mayeli M, Shafie M et al (2022) Memantine administration in patients with optic neuritis: a double blind randomized clinical trial. Graefe\u2019s Arch Clinic Exp Ophthalmol 260(12):3969\u20133975. https:\/\/doi.org\/10.1007\/s00417-022-05720-8","journal-title":"Graefe\u2019s Arch Clinic Exp Ophthalmol"},{"issue":"1","key":"3447_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1352458511415452","volume":"18","author":"A Tsakiri","year":"2012","unstructured":"Tsakiri A, Kallenbach K, Fugl\u00f8 D, Wanscher B, Larsson H, Frederiksen J (2012) Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Mult Scler J 18(1):72\u201381. https:\/\/doi.org\/10.1177\/1352458511415452","journal-title":"Mult Scler J"},{"key":"3447_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/2055217319850193","author":"J Falardeau","year":"2019","unstructured":"Falardeau J, Fryman A, Wanchu R et al (2019) Oral lipoic acid as a treatment for acute optic neuritis: a blinded, placebo controlled randomized trial. Mult Scler J Exp Transl Clin. https:\/\/doi.org\/10.1177\/2055217319850193","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"2","key":"3447_CR23","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/1352458517742979","volume":"25","author":"JB McKee","year":"2019","unstructured":"McKee JB, Cottriall CL, Elston J et al (2019) Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial. Mult Scler J 25(2):246\u2013255. https:\/\/doi.org\/10.1177\/1352458517742979","journal-title":"Mult Scler J"},{"key":"3447_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01645-z","author":"C Albert","year":"2020","unstructured":"Albert C, Mikolajczak J, Liekfeld A et al (2020) Fingolimod after a first unilateral episode of acute optic neuritis (MOVING)\u2014preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial. BMC Neurol. https:\/\/doi.org\/10.1186\/s12883-020-01645-z","journal-title":"BMC Neurol"},{"issue":"3","key":"3447_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(16)30377-5","volume":"16","author":"D Cadavid","year":"2017","unstructured":"Cadavid D, Balcer L, Galetta S et al (2017) Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 16(3):189\u2013199. https:\/\/doi.org\/10.1016\/S1474-4422(16)30377-5","journal-title":"Lancet Neurol"},{"issue":"18","key":"3447_CR26","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1212\/01.wnl.0000260612.51849.ed","volume":"68","author":"J Sepulcre","year":"2007","unstructured":"Sepulcre J, Murie-Fernandez M, Salinas-Alaman A, Garc\u00eda-Layana A, Bejarano B, Villoslada P (2007) Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology 68(18):1488\u20131494. https:\/\/doi.org\/10.1212\/01.wnl.0000260612.51849.ed","journal-title":"Neurology"},{"issue":"6","key":"3447_CR27","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/ana.22005","volume":"67","author":"LS Talman","year":"2010","unstructured":"Talman LS, Bisker ER, Sackel DJ et al (2010) Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol 67(6):749\u2013760. https:\/\/doi.org\/10.1002\/ana.22005","journal-title":"Ann Neurol"},{"issue":"6","key":"3447_CR28","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ana.20851","volume":"59","author":"F Costello","year":"2006","unstructured":"Costello F, Coupland S, Hodge W et al (2006) Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 59(6):963\u2013969. https:\/\/doi.org\/10.1002\/ana.20851","journal-title":"Ann Neurol"},{"key":"3447_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.574748","author":"CWR Turalde","year":"2021","unstructured":"Turalde CWR, Espiritu AI, Anlacan VMM (2021) Memantine for multiple sclerosis: a systematic review and meta-analysis of randomized trials. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2020.574748","journal-title":"Front Neurol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03447-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03447-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03447-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:03:48Z","timestamp":1766167428000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03447-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3447"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03447-z","relation":{},"ISSN":["1573-2630"],"issn-type":[{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"80"}}